The study of Brensocatib in participants with hepatic impairment
The company Insmed Incorporated is enrolling patients into the clinical trial investigating A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment.
The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.
The trial is designed to enroll male and female 18 Years to 70 Years and is being conducted in the USA002, Rialto, California, United States; USA003, Orlando, Florida, United States; USA001, San Antonio, Texas, United States.
The study start date is August 26, 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05517525.
